mTOR signaling in mice with dysfunctional cardiac ryanodine receptor ion channel

References

• Wehrens XH, Lehnart SE, Marks AR. Intracellular calcium release and cardiac disease. Annu Rev Physiol. 2005;67:69–98.
   PubMed Web of Science ®Google Scholar
• Meissner G. Molecular regulation of cardiac ryanodine receptor ion channel. Cell Calcium. 2004;35:621–628.
   PubMed Web of Science ®Google Scholar
• Hamilton SL, Serysheva II. Ryanodine receptor structure: progress and challenges. J Biol Chem. 2009;284:4047–4051.
   PubMed Web of Science ®Google Scholar
• Fruen BR, Bardy JM, Byrem TM, Strasburg GM, Louis CF. Differential Ca(2+) sensitivity of skeletal and cardiac muscle ryanodine receptors in the presence of calmodulin. Am J Physiol Cell Physiol. 2000;279:C724–C733.
   Web of Science ®Google Scholar
• Balshaw DM, Xu L, Yamaguchi N, Pasek DA, Meissner G. Calmodulin binding and inhibition of cardiac muscle calcium release channel (ryanodine receptor). J Biol Chem. 2001;276:20144–20153.
   PubMed Web of Science ®Google Scholar
• Dorn GW 2nd, Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest. 2005;115:527–537.
   PubMed Web of Science ®Google Scholar
• Eder P, Molkentin JD. TRPC channels as effectors of cardiac hypertrophy. Circ Res. 2011;108:265–272.
   PubMed Web of Science ®Google Scholar
• Kudoh S, Akazawa H, Takano H, et al. Stretch-modulation of second messengers: effects on cardiomyocyte ion transport. Progr Biophys Mol Biol. 2003;82:57–66.
   PubMed Web of Science ®Google Scholar
• Yamaguchi N, Takahashi N, Xu L, Smithies O, Meissner G. Early cardiac hypertrophy in mice with impaired calmodulin regulation of cardiac muscle Ca2+ release channel. J Clin Invest. 2007;117:1344–1353.
   Web of Science ®Google Scholar
• Arnáiz-Cot JJ, Damon BJ, Zhang XH, et al. Cardiac calcium signaling pathologies associated with defective calmodulin regulation of type 2 ryanodine receptor. J Physiol. 2013;591:4287–4299.
   Web of Science ®Google Scholar
• Foster KG, Fingar DC. Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J Biol Chem. 2010;285:14071–14077.
   Web of Science ®Google Scholar
• Ma XM, Blenis J. Molecular mechanisms of mTOR mediated translational control. Nat Rev Mol Cell Biol. 2009;10:307–318.
   PubMed Web of Science ®Google Scholar
• McMullen JR, Shioi T, Zhang L, et al. Deletion of ribosomal S6 kinases does not attenuate pathological, physiological, or insulin-like growth factor 1 receptor-phosphoinositide 3-kinase-induced cardiac hypertrophy. Mol Cell Biol. 2004;24:6231–6240.
   PubMed Web of Science ®Google Scholar
• Banaszynski LA, Liu CW, Wandless TJ. Characterization of the FKBP.rapamycin.FRB ternary complex. J Am Chem Soc. 2005;127:4715–4721.
   PubMed Web of Science ®Google Scholar
• Shioi T, McMullen JR, Tarnavski O, et al. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation. 2003;107:1664–1670.
   PubMed Web of Science ®Google Scholar
• Sutko JL, Airey JA, Welch W, Ruest L. The pharmacology of ryanodine and related compounds. Pharmacol Rev. 1997;49:53–98.
   PubMed Web of Science ®Google Scholar
• Gingras AC, Raught B, Gygi SP, et al. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev. 2001;15:2852–2864.
   PubMed Web of Science ®Google Scholar
• Aoyagi T, Matsui T. Phosphoinositide-3 kinase signaling in cardiac hypertrophy and heart failure. Curr Pharm Des. 2011;17:1818–1824.
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Stephens L, Hawkins P. PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol. 2012;13:195–203.
   PubMed Web of Science ®Google Scholar
• Torres J, Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J Biol Chem. 2001;276:993–998.
   PubMed Web of Science ®Google Scholar
• Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J. 2008;412:179–190.
   PubMed Web of Science ®Google Scholar
• Kaftan E, Marks AR, Ehrlich BE. Effects of rapamycin on ryanodine receptor/Ca(2+)-release channels from cardiac muscle. Circ Res. 1996;78:990–997.
   PubMed Web of Science ®Google Scholar
• Yamaguchi N, Chakraborty A, Pasek DA, Molkentin JD, Meissner G. Dysfunctional ryanodine receptor and cardiac hypertrophy: role of signaling molecules. Am J Phys Heart Circ Physiol. 2011;300:H2187–H2895.
   Web of Science ®Google Scholar
• Gao XM, Wong G, Wang B, et al. Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis. J Hypertens. 2006;24:1663–1670.
   PubMed Web of Science ®Google Scholar
• Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci U S A. 2008;105:17414–17419.
   PubMed Web of Science ®Google Scholar
• Yang Y, Guo T, Oda T, et al. Cardiac myocyte Z-line calmodulin is mainly RyR2-bound, and reduction is arrhythmogenic and occurs in heart failure. Circ Res. 2014;114:295–306.
   Web of Science ®Google Scholar
• Nomikos M, Thanassoulas A, Beck K, et al. Altered RyR2 regulation by the calmodulin F90L mutation associated with idiopathic ventricular fibrillation and early sudden cardiac death. FEBS Lett. 2014;588:2898–2902.
   Web of Science ®Google Scholar
• Hwang HS, Nitu FR, Yang Y, et al. Divergent regulation of ryanodine receptor 2 calcium release channels by arrhythmogenic human calmodulin missense mutants. Circ Res. 2014;114:1114–1124.
   PubMed Web of Science ®Google Scholar
• Nyegaard M, Overgaard MT, Søndergaard MT, et al. Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death. Am J Hum Genet. 2012;91:703–712.
   PubMed Web of Science ®Google Scholar
• Makita N, Yagihara N, Crotti L, et al. Novel calmodulin mutations associated with congenital arrhythmia susceptibility. Circ Cardiovasc Genet. 2014;7:466–474.
   PubMedGoogle Scholar
• Crotti L, Johnson CN, Graf E, et al. Calmodulin mutations associated with recurrent cardiac arrest in infants. Circulation. 2013;127:1009–1017.
   PubMed Web of Science ®Google Scholar
• Xu X, Yano M, Uchinoumi H, et al. Defective calmodulin binding to the cardiac ryanodine receptor plays a key role in CPVT-associated channel dysfunction. Biochem Biophys Res Comm. 2010;394:660–666.
   PubMed Web of Science ®Google Scholar
• Fukuda M, Yamamoto T, Nishimura S, et al. Enhanced binding of calmodulin to RyR2 corrects arrhythmogenic channel disorder in CPVT-associated myocytes. Biochem Biophys Res Comm. 2014;448:1–7.
   Web of Science ®Google Scholar
• Hino A, Yano M, Kato T, et al. Enhanced binding of calmodulin to the ryanodine receptor corrects contractile dysfunction in failing hearts. Cardiovasc Res. 2012;96:433–443.
   Web of Science ®Google Scholar
• Hwang SY, Wei J, Westhoff JH, et al. Differential functional interaction of two Vesl/Homer protein isoforms with ryanodine receptor type 1: a novel mechanism for control of intracellular calcium signaling. Cell Calcium. 2003;34:177–184.
   PubMed Web of Science ®Google Scholar